News Sentiment

INCY sentiment intelligence

Incyte Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 98.22 Week of 19 Jun 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-9.5% over one week, +1.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -9.5% Price reacting lower
Trend fit Trend inactive 1.1% over four weeks
Fair value 34.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 29
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 6
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 9
TradingView 6
AD HOC NEWS 6
Market source 6
TradingKey 4
Stock Titan 3
ChartMill 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 18
Analyst action 8
Regulatory and legal 4
Deals and strategy 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Investing.com Direct company coverage

Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit

Incyte Corporation has settled a Medicaid rebate litigation with the Centers for Medicare & Medicaid Services (CMS), expecting a one-time non-cash benefit of approximately $246 million in the second quarter of 2026. The settlement resolves a dispute over the application of Medica

Tone
Positive 75/100
Event
Earnings
Published
22 Jun 2026 11:37
Source
Investing.com
TradingView Direct company coverage

Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling

Incyte announced a settlement with CMS regarding its drug Opzelura, which will not be treated as a line extension of Jakafi under Medicaid rebate rules. This agreement will result in a one-time non-cash benefit of approximately $246 million in Q2 2026 for Incyte, stemming from th

Tone
Positive 74/100
Event
Market update
Published
22 Jun 2026 11:03
Source
TradingView
Investing.com India Direct company coverage

BMO upgrades Incyte stock rating on strategic progress By Investing.com

BMO Capital upgraded Incyte Corp. (NASDAQ:INCY) from Underperform to Market Perform, raising its price target to $94 from $75, citing significant strategic progress under new leadership. This upgrade follows a prior downgrade due to concerns about the loss of exclusivity for Jaka

Tone
Positive 73/100
Event
Analyst action
Published
22 Jun 2026 09:38
Source
Investing.com India
Barchart.com Direct company coverage

Incyte Stock: Is INCY Outperforming the Healthcare Sector?

Incyte Corporation (INCY) is outperforming the broader healthcare sector, with its stock rising 6.5% over the past three months compared to the State Street Healthcare Select Sector SPDR ETF’s (XLV) 1.5% increase. Over the past year, INCY surged 43.9% against XLV's 12.1% rally. T

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 09:37
Source
Barchart.com
grafa.com Direct company coverage

Incyte secures Japanese approval for lymphoma drug Minjuvi

Incyte has received regulatory approval in Japan for its lymphoma treatment combination Minjuvi, which achieved response rates up to 71.4% in clinical trials. This approval provides a new treatment option for patients with relapsed or refractory large B-cell lymphoma, especially

Tone
Positive 74/100
Event
Regulatory and legal
Published
19 Jun 2026 10:19
Source
grafa.com
TradingKey Direct company coverage

Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Incyte Corp (INCY), highlighting its current price momentum score, support and resistance levels, and various technical indicators. It details the readings for MACD, RSI, KDJ, and others, along with moving averages, to suggest an over

Tone
Negative 40/100
Event
Market update
Published
19 Jun 2026 09:37
Source
TradingKey
Stock Titan Direct company coverage

Japan clears Incyte’s Minjuvi for relapsed DLBCL patients

Incyte Biosciences Japan G.K. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval is b

Tone
Positive 71/100
Event
Regulatory and legal
Published
19 Jun 2026 06:03
Source
Stock Titan
TradingView Direct company coverage

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Mirum Pharmaceuticals (MIRM) and Incyte Corporation (INCY) announced positive phase II results from their PROGRESS study for zilurgisertib, an investigational oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP).

Tone
Positive 71/100
Event
Regulatory and legal
Published
17 Jun 2026 10:37
Source
TradingView
TradingKey Direct company coverage

Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Incyte Corp (INCY), highlighting its current earnings forecast score of 7.14 within the Pharmaceuticals industry and an average price target of $101.00 based on 28 analysts. The majority of analysts recommend a "Buy" for INCY, with e

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 06:38
Source
TradingKey
TradingKey Direct company coverage

Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis

Incyte Corp (INCY) has a robust financial health score of 9.25, ranking 7th out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 20.87% to $1.27 billion, with net profit soaring by 91.73%. These figures indicate strong

Tone
Positive 76/100
Event
Earnings
Published
17 Jun 2026 06:08
Source
TradingKey
TradingKey Direct company coverage

Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk

Incyte Corp (INCY) has a risk assessment score of 8.15, ranking 27 out of 157 in the Pharmaceuticals industry. The company's beta of 0.79 indicates it tends to underperform in up markets but has smaller declines in down markets. The U.S. Dollar Index's neutral state has a neutral

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jun 2026 06:08
Source
TradingKey
The Globe and Mail Direct company coverage

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)

Analysts have issued conflicting ratings for several healthcare stocks. Incyte (INCY) received a Hold rating from Wells Fargo, with a Moderate Buy consensus. Intellia Therapeutics (NTLA) was rated Buy by TD Cowen, holding a Moderate Buy consensus. Halozyme (HALO) also received a

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jun 2026 11:07
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX)

Barclays analysts have provided insights on several healthcare companies. Etzer Darout maintained a Buy rating for Incyte (INCY) with a $117.00 price target, while Emily Field issued a Sell rating for Pfizer (PFE) with a $25.00 price target. Eliana Merle maintained a Buy rating o

Tone
Positive 63/100
Event
Analyst action
Published
16 Jun 2026 08:40
Source
The Globe and Mail
Investing.com Direct company coverage

BMO reiterates Incyte stock Underperform on ET/MF trial data

BMO Capital reiterated an Underperform rating on Incyte Corp. with a $75.00 price target following updates on its mCALR antibody candidate, '989. The firm noted decreased efficacy in larger patient groups for essential thrombocythemia and mild regression in myelofibrosis monother

Tone
Negative 37/100
Event
Analyst action
Published
16 Jun 2026 04:37
Source
Investing.com
Stock Traders Daily Direct company coverage

Behavioral Patterns of INCY and Institutional Flows

The article analyzes Incyte Corporation (INCY) with a strong overweight bias based on AI-generated signals across all time horizons. It identifies a mid-channel oscillation pattern and presents an exceptional short setup with a 34.6:1 risk-reward ratio. The analysis further detai

Tone
Positive 74/100
Event
Market update
Published
16 Jun 2026 02:50
Source
Stock Traders Daily
Quiver Quantitative Direct company coverage

Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take

Incyte (INCY) shares dropped 6.0% after investors reviewed updated clinical trial data for INCA033989, a mutant CALR-targeted antibody. Despite the company highlighting rapid and durable responses in essential thrombocythemia (ET) and myelofibrosis (MF), the stock reacted to perc

Tone
Negative 35/100
Event
Analyst action
Published
15 Jun 2026 21:20
Source
Quiver Quantitative
MarketWatch Direct company coverage

Incyte Corp. stock underperforms Monday when compared to competitors

Incyte Corp. (INCY) shares decreased by 6.04% to $101.98 on Monday, despite a generally positive trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. This fall ended a four-day winning streak for the company's stock.

Tone
Negative 28/100
Event
Market update
Published
15 Jun 2026 20:30
Source
MarketWatch
AlphaStreet Direct company coverage

Why Incyte Is Dropping 5.6%: HC Wainwright & Co. Maintains Buy

Incyte Corporation's shares plunged 5.6% despite HC Wainwright & Co. maintaining a Buy rating and increasing its price target from $135 to $140. The market's reaction, with heavy trading volume, suggests investors are focusing on broader sector weakness, potential FDA regulatory

Tone
Negative 37/100
Event
Analyst action
Published
15 Jun 2026 19:44
Source
AlphaStreet
TradingView Direct company coverage

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum Pharmaceuticals (MIRM) and Incyte Corporation (INCY) announced positive Phase II results for zilurgisertib, an investigational oral ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP). The drug significantly reduced new heterotopic ossification lesions, with the

Tone
Positive 71/100
Event
Regulatory and legal
Published
15 Jun 2026 15:09
Source
TradingView